Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome.

Autor: Martínez-Castillo R; Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, Spain., González-Gallardo C; Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, Spain., Muñoz-Ávila JI; Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, Spain., Font P; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Medical and Surgical Sciences, School of Medicine, University of Cordoba, 14004 Cordoba, Spain., Villalba-González M; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain., Stoikow I; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain., Fernández-Choquet de Isla I; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain., Pugliese F; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain., Anaya-Alaminos R; Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, Spain., García-Serrano JL; Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, Spain., Hermoso-Fernández F; Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, Spain., Contieri F; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain., Muñoz-de-Escalona-Rojas JE; Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, Spain., Pérez-Fajardo L; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain., Blanco-Blanco M; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain., Jiménez-Gómez Y; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain. Electronic address: yolanda.jimenez@imibic.org., González-Andrades M; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Medical and Surgical Sciences, School of Medicine, University of Cordoba, 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain. Electronic address: mgandrades@uco.es.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Apr; Vol. 160, pp. 114368. Date of Electronic Publication: 2023 Feb 06.
DOI: 10.1016/j.biopha.2023.114368
Abstrakt: Purpose: To evaluate long-term visual and anatomical outcomes in neovascular age-related macular degeneration (nAMD) patients treated with anti-vascular endothelial growth factor (VEGF) agents depending on the time delay from confirmed diagnosis to treatment initiation.
Materials and Methods: Seventy-three nAMD patients (73 eyes) treated with anti-VEGF agents for 12 months using the pro re nata regimen were included in this retrospective longitudinal study. Patients were split into 3 groups according to the time from diagnosis to first anti-VEGF injection: < 48 h (group 1); 48 h-7 days (group 2); > 7 days (group 3). Decimal best-corrected visual acuity (VA) and macular thickness (MT) were recorded at baseline and 1-2-, 3-4-, 6- and 12-month later. Furthermore, age, gender as well as the applied treatment and number of injections after 12 months of treatment were also registered and compared.
Results: Long-term effect of the treatment demonstrated enhanced VA in group 1 patients compared with the rest of groups after 1-2-, 6-, and 12-month follow-up (P < 0.05). Positive effects of early treatment were additionally corroborated by the augmented percentage of patients with normal VA in the group 1 respect to the rest of groups over studied time points (P < 0.05). Moreover, the VA gain in nAMD at group 1 was obtained with a mean of 3.7 intravitreal injections over 1-year follow-up period. Regarding MT, non-significant difference was observed among groups.
Conclusions: An early initial treatment with VEGF inhibitors is critical to achieve the best functional benefits of this therapy in new-onset nAMD patients.
Competing Interests: Conflict of interest statement The authors declare that there are no conflicts of interest.
(Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: